Voglibose 0.3mg Tablet in PCD pharma franchise in Hyderabad

Voglibose 0.3mg Tablet in pharmaceutical manufacturing company in Mumbai

Voglibose 0.3mg Tablet in pharma franchise in Pune

Voglibose 0.3mg Tablet in pharma suppliers in Delhi

Voglibose 0.3mg Tablet in pharma export companies in Kolkata
Voglibose 0.3mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /voglibose-i-point-p-point-0-point-3-tablets

About the Product

Description


Vogliviga 0.3 Tablet contains Voglibose 0.3mg, an alpha-glucosidase inhibitor used to control postprandial (after meal) blood sugar levels in patients with type 2 diabetes mellitus. It works by delaying the breakdown and absorption of complex carbohydrates in the small intestine, thereby reducing the rise in blood glucose after meals. This makes it an effective add-on therapy to diet, exercise, and other oral antidiabetic agents, especially for managing postprandial hyperglycemia.

Common side effects include flatulence, abdominal discomfort, bloating, and mild diarrhea. These effects usually subside as the body adjusts to the medication. Serious gastrointestinal effects are rare.

Indicated for type 2 diabetes mellitus patients, particularly for controlling post-meal blood sugar spikes in combination with other antidiabetic medications.

Not suitable for individuals with gastrointestinal disorders like inflammatory bowel disease, intestinal ulcers, or chronic digestive problems. Blood sugar levels should be monitored regularly. Use with caution in patients with liver or kidney impairment.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of the reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Vogliviga 0.3 Tablet (Voglibose 0.3mg) in the PCD pharma franchise market?

Vogliviga 0.3 Tablet has strong demand in the anti-diabetic and metabolic care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on diabetology and chronic-care portfolios.

Why should medical distributors include Vogliviga 0.3 Tablet in their product range?

Medical distributors and agencies can benefit from consistent demand for management of type 2 diabetes mellitus and post-meal (postprandial) blood sugar control. Voglibose 0.3mg helps reduce absorption of carbohydrates and controls after-meal blood sugar spikes This supports better glycemic control and strengthens a reliable anti-diabetic portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Vogliviga 0.3 Tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Vogliviga 0.3 Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for Vogliviga 0.3 Tablet?

Wholesalers and medical agencies benefit from strong diabetologist prescriptions, steady chronic-care demand, large diabetic patient base, reliable supply chain support, and good margins in anti-diabetic medicines.

How can I become a distributor or franchise partner for Vogliviga 0.3 Tablet?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.